Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback